Osseous binding compounds

Antibiotic compounds binding to bone via a CSA-conjugated linker address the challenges of treating bone infections by providing localized antibiotic action, reducing systemic side effects and antibiotic resistance.

JP7580815B2Active Publication Date: 2024-11-12BRIGHAM YOUNG UNIV
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
JP2022504548
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2019-07-24
Filing Date
2020-07-24
Publication Date
2024-11-12
Estimated Expiration
2040-07-24

AI Technical Summary

Technical Problem

Treating bone infections is complicated due to low vascularization and location beneath soft tissues, requiring high systemic drug doses with harmful side effects and leading to antibiotic-resistant strains, while local delivery methods are experimental and invasive.

Method used

Development of antibiotic compounds that bind to bone through a cationic steroid antimicrobial (CSA) conjugated to an osteointegration moiety via a linker, targeting the bone site for localized antibiotic action.

Benefits of technology

Reduces systemic drug concentrations, minimizes side effects, and effectively treats bone infections and promotes bone formation by targeting antibiotics directly to the bone site, reducing the risk of antibiotic resistance.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007580815000018
    Figure 0007580815000018
  • Figure 0007580815000019
    Figure 0007580815000019
  • Figure 0007580815000020
    Figure 0007580815000020
Patent Text Reader

Abstract

Disclosed herein are compounds having the following formula (I): BLC(I), or pharmaceutically acceptable salt forms thereof, pharmaceutical compositions comprising said compounds, and methods of using said compounds or pharmaceutical compositions for treating infection or osteomyelitis in the bone of a subject, promoting bone formation in a subject, or treating bone cancer or metastatic bone cancer in a subject.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present disclosure relates to antibiotic compounds, particularly those that bind to bone and are useful in the treatment of bone infections. [Background technology]

[0002] Any discussion of prior art throughout this specification should in no way be considered as an admission that such prior art is widely known or forms part of the common general knowledge in the field.

[0003] Infection of open fractures is a major cause of morbidity and mortality worldwide (Tay et al. Injury. 2014.45:1653-1658; Wu. Othrop Res Rev. 2013.5:21-33). Even if the wound is apparently uncontaminated, open fractures generally have a higher risk of infection compared to comparable closed fractures. Bone infections can also occur in the absence of a fracture. For example, in osteomyelitis, bacteria can reach the bone by spreading via the bloodstream or from nearby tissues, such as from a diabetic foot infection. Infections can also occur in bone following trauma that exposes the bone to bacteria. In addition, implants can cause bone infections.

[0004] Treating bone infections is complicated due to their relatively low vascularization and their location beneath soft tissues within the body. High doses of systemic drugs and long-term treatment regimens may be required to provide effective concentrations of drugs at the site of infection. However, this can result in adverse side effects, limiting the use of certain antibiotics. Localized delivery of antibiotics to the surgical site has been explored, but this approach is still experimental and requires an open surgical site. Furthermore, extensive antibiotic use over time has led to the development of antibiotic-resistant strains of bacteria. The occurrence of community-acquired antibiotic-resistant strains, e.g., methicillin-resistant Staphylococcus aureus, methicillin-resistant Staphylococcus epidermidis, vancomycin-resistant Staphylococcus spp., and tobramycin-resistant Pseudomonas aeruginosa, is expanding, with rates of up to 25% reported in the United States (Chen et al. Clin Orthop Relat Res. 2013. 471:3135-3140; Stevens. Curr Opin Infect Dis. 2003. 16:189-191). Summary of the Invention [Problem to be solved by the invention]

[0005] In this context, there is a need for new antibiotics and antibiotic treatments, particularly for orthopedic applications. [Means for solving the problem]

[0006] The present disclosure relates to antibiotic compounds, particularly antibiotic compounds that bind to bone and are useful in the treatment of bone infection.In the research that leads to the present disclosure, the inventors conjugate cationic steroid antibacterial (CSA) to bone-binding moiety via a linker.The bone-binding moiety targets the CSA moiety to bone, thereby increasing its concentration at the bone infection site, both for the treatment of existing infection and for prevention against subsequent infection or prevention in cases of high infection risk.

[0007] The following formula (I): BLC (I) where B is a bone-binding moiety; L is a linker; and C is a cationic steroid antimicrobial (CSA) moiety. or a pharma- ceutically acceptable salt form thereof.

[0008] In some embodiments, the CSA is selected from the group consisting of CSA-8, CSA-13, CSA-44, CSA-90, CSA-91, CSA-124, CSA-131, CSA-133, CSA-138, CSA-142, CSA-144, CSA-190, CSA-191, and CSA-192. In some embodiments, the CSA is CSA-90.

[0009] In some embodiments, the bone-binding moiety is a bisphosphonate, such as a bisphosphonate selected from the group consisting of etidronate, clodronate, tiludronate, pamidronate, medronate, etidronate, neridronate, olpadronate, alendronate, ibandronate, aminomethylenediphosphonate, risedronate, and zoledronate. In some embodiments, the bisphosphonate is selected from the group consisting of alendronate, pamidronate, and neridronate. In some embodiments, the bisphosphonate is alendronate.

[0010] In some embodiments, the linker is hydrophilic. In some embodiments, the linker has a molecular weight of less than about 2 kDa. In some embodiments, the linker comprises polyethylene glycol (PEG), for example, the linker has the structure of formula (II):

[0011] [ka]

[0012] (In the formula, X is independently selected from O and S; T is absent or is an alkanediyl group having 1 to 15 carbon atoms; Y is absent or is an alkanediyl group having 1 to 15 carbon atoms; n is an integer from 1 to 30; The wavy lines represent the attachment points to the CSA and bone junction. has.

[0013] In some embodiments, X is O. In some embodiments, T is an alkanediyl group having 1 to 15 carbon atoms. In some embodiments, Y is an alkanediyl group having 1 to 15 carbon atoms. In some embodiments, T is an alkanediyl group having 1 to 6 carbon atoms. In some embodiments, Y is an alkanediyl group having 1 to 6 carbon atoms. In some embodiments, n is an integer from 10 to 20.

[0014] In some embodiments, the compound has the structure of Formula (III):

[0015] [ka]

[0016] (wherein n is 1 to 50). In some embodiments, n is 1 to 30. In some embodiments, the compound has a molecular weight of about 1.5 kDa to about 2.5 kDa.

[0017] In some embodiments, the compound has the structure of Formula (IV):

[0018] [ka]

[0019] has. Also provided is a pharmaceutical composition comprising a compound disclosed herein and a pharma- ceutically acceptable carrier. In some embodiments, the composition is suitable for systemic administration. In some embodiments, the composition is suitable for oral or parenteral administration. In some embodiments, the composition is suitable for intravenous administration.

[0020] Also provided is a method for treating bone infection in a subject, comprising administering to the subject a compound or pharmaceutical composition disclosed herein. In some embodiments, the infection is a bacterial infection, such as a Staphylococcus aureus infection, a Staphylococcus epidermidis infection, or a Pseudomonas aeruginosa infection. In some embodiments, the bone comprises a fracture.

[0021] Also provided is a method of treating osteomyelitis in a subject, comprising administering to the subject a compound or pharmaceutical composition disclosed herein, hi some embodiments, the osteomyelitis is associated with Staphylococcus aureus, Staphylococcus epidermidis, or Pseudomonas aeruginosa infection.

[0022] Also provided is a method for promoting bone formation in a subject, comprising administering to the subject a compound or pharmaceutical composition disclosed herein. In some embodiments, the subject suffers from a bone disorder selected from the group consisting of bone fracture, spinal cord injury, spinal disc degeneration, Paget's disease, bone cancer, metastatic bone cancer, and osteoporosis. In some embodiments, the subject's bone is infected with one or more bacteria, such as one or more of Staphylococcus aureus, Staphylococcus epidermidis, or Pseudomonas aeruginosa.

[0023] In some embodiments, the compound or pharmaceutical composition is administered systemically to the subject. In some embodiments, the compound or pharmaceutical composition is administered orally or parenterally to the subject. In some embodiments, the compound or pharmaceutical composition is administered intravenously to the subject. In some embodiments, the subject is a mammal. In some embodiments, the subject is a human.

[0024] Also provided is the use of a compound or pharmaceutical composition disclosed herein in the manufacture of a medicament for the treatment of a bone infection in a subject. Also provided is the use of a compound or pharmaceutical composition disclosed herein in the manufacture of a medicament for the treatment of osteomyelitis in a subject.

[0025] Also provided is the use of a compound or pharmaceutical composition disclosed herein in the manufacture of a medicament for promoting bone formation in a subject. Also provided is the use of a compound or pharmaceutical composition disclosed herein in the manufacture of a medicament for the treatment of bone cancer or metastatic bone cancer in a subject. Aspects of the invention Aspect 1 The following formula (I): BLC (I) (In the formula, B is the osseointegrated part; L is a linker; C is a cationic steroid antimicrobial (CSA) moiety. or a pharma- ceutically acceptable salt form thereof. Aspect 2 The compound of embodiment 1, wherein the CSA is selected from the group consisting of CSA-8, CSA-13, CSA-44, CSA-90, CSA-91, CSA-124, CSA-131, CSA-133, CSA-138, CSA-142, CSA-190, CSA-191, and CSA-192, e.g., the CSA is CSA-13, CSA-90, or CSA-131, preferably CSA-90. Aspect 3 The compound of aspect 1 or 2, wherein the bone-binding moiety is a bisphosphonate, e.g., the bisphosphonate is selected from the group consisting of etidronate, clodronate, tiludronate, pamidronate, medronate, etidronate, neridronate, olpadronate, alendronate, ibandronate, aminomethylene diphosphonate, risedronate, and zoledronate, preferably the bisphosphonate is selected from the group consisting of alendronate, pamidronate, and neridronate, more preferably the bisphosphonate is alendronate. Aspect 4 The compound according to any one of aspects 1 to 3, wherein the linker is hydrophilic. Aspect 5 The compound according to any one of aspects 1 to 4, wherein the linker has a molecular weight of less than about 2 kDa. Aspect 6 The compound of any one of aspects 1 to 5, wherein the linker comprises polyethylene glycol (PEG). Aspect 7 The linker has the following structure:

change

change

change

[0026] [Figure 1] Figure 1A is the HPLC profile of BBA-1, Figure 1B is the HPLC profile of pure NHS-PEG-COOH linker, and Figure 1C is the HPLC profile of pure CSA-90. [Diagram 2] Figure 2A is an FT-IR spectrum of alendronate, Figure 2B is an FT-IR spectrum of CSA-90, Figure 2C is an FT-IR spectrum of NHS-PEG-COOH linker, and Figure 2D is an FT-IR spectrum of BBA-1. [Figure 3A] FIG. 3A is a 1H NMR spectrum of BBA-1, NHS-PEG-COOH linker, CSA-90, and alendronate. [Figure 3B] FIG. 3B is the 31P NMR spectrum of BBA-1 and alendronate. [Figure 4] Figure 4A shows Kirby Bauer assays for S. aureus and MRSA (results are from a single experiment containing triplicate samples). Figure 4B shows representative images of inhibition zones (Kirby Bauer assays for S. aureus and MRSA). Figure 4C shows MICs and MBCs for CSA-90 and BBA-1. [Diagram 5] Figure 5A shows an HA binding assay, and Figure 5B shows an HA binding assay. [Figure 6] FIG. 6 shows an alkaline phosphatase activity assay (p-nitrophenyl phosphate) to test the osteogenic promoting effect of BBA-1 on cultured osteoblasts. [Figure 7] FIG. 7 shows protein prenylation assays demonstrating the lack of effect on the mevalonate pathway by BBA-1 and CSA-90. [Figure 8]FIG. 8 presents data from a toxicity study on BBA-1 administered to mice exhibiting infection by soft tissue swab assay. [Figure 9] FIG. 9 presents data from a toxicity study on BBA-1 administered to mice exhibiting infection via the leg assay. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0027] definition The articles "a" and "an" are used herein to refer to one or to more than one (ie, to at least one) of the grammatical object of the article.

[0028] The term "about" is understood to refer to a range of ±10%, for example ±5%, or ±1%, or ±0.1%. The terms "simultaneous administration" or "administering simultaneously" or "co-administering" and the like refer to administration of a single composition containing two or more active agents, or administration of each active agent contemporaneously, simultaneously or sequentially, as separate compositions and / or delivered by separate routes, within a period of time sufficiently short that effective results are comparable to those obtained when all such active agents are administered as a single composition. By "concurrently" it is meant that the active agents are administered at substantially the same time, preferably together in the same formulation.

[0029] In this specification and claims, the words "comprise", "comprises", "comprised" or "comprising", "including", or "having", and the like, are used in the inclusive sense, i.e., to specify the presence of specified features but not to exclude the presence of additional or further features.

[0030] The term "pharmaceutically acceptable" as used herein refers to a material that does not induce a substantial, adverse allergic or immunological response when administered to a subject. "Pharmaceutically acceptable carriers" include, but are not limited to, solvents, coatings, dispersing agents, wetting agents, isotonic and absorption delaying agents, and disintegrants.

[0031] "Prevention" includes reducing the risk, occurrence, and / or severity of a condition or disorder. The terms "treatment" and "treating" include both preventative or preventive treatments (preventing and / or delaying the onset of the targeted pathological condition or disorder), as well as curative, therapeutic, or disease-modifying treatments, including therapeutic measures that cure, slow, reduce, and / or stop the progression of the symptoms of a pathological condition or disorder; as well as treatment of patients at risk of or suspected of having a disease, and patients who are ill or diagnosed as suffering from a disease or medical condition. The terms "treatment" and "treating" do not necessarily mean that a subject is treated until complete recovery. The terms "treatment" and "treating" also refer to the maintenance and / or promotion of the health of individuals who are not suffering from a disease but may be susceptible to developing an unhealthy condition. The terms "treatment" and "treating" are also intended to include the enhancement or otherwise of one or more primary preventive or therapeutic measures. By way of non-limiting example, the treatment may be performed by the patient, a caregiver, a doctor, a nurse, or another medical professional.

[0032] The term "alkanediyl" refers to a group of the formula C n H 2n It is understood to refer to a divalent saturated branched or straight chain hydrocarbon radical consistent with

[0033] Cationic steroid antibacterial moiety Cationic steroid antimicrobials (CSAs) or ceragenins are synthetic compounds designed to mimic the activity of endogenous antibacterial peptides. They are typically cationic and have a broad spectrum of antibacterial activity, including activity against bacteria, fungi, and viruses, as well as anti-inflammatory and immunomodulatory activity. Over 100 types of CSAs have been synthesized.

[0034] Also, CSAs such as CSA-13, CSA-90, and CSA-131 have been reported to promote or enhance bone formation (US Pat. No. 9,694,019; Schindeler et al. J Bone Joint Surg Am. 2015.97(4):302-309). Bone is a dynamic tissue whose homeostasis represents an equilibrium between bone formation and bone resorption. In bone formation, adult stem cells differentiate into osteoprogenitor cells (i.e., osteocyte precursor cells), which mature into osteoblasts, osteocytes, and have the ability to form mature bone and mineralized bone matrix. In bone resorption, osteoclasts (cells that resorb bone tissue) degrade the mineralized bone matrix and create cavities on the bone surface. Despite the ability of bone tissue to rejuvenate itself, repairing nonunion fractures and regenerating bone defects remains a major challenge. In fact, bone is currently second only to blood as the most transplanted tissue. In this regard, the compounds described herein may be useful for promoting bone formation and / or treating bone disorders.

[0035] CSA-90 is a synthetic small peptidomimetic compound based on endogenous cationic antibacterial peptides such as the human cathelicidin LL-37. LL-37 is found in airway mucus and is thought to play an important role in controlling bacterial growth in the lungs. The steroid-like structure of CSA-90 allows it to disrupt cell membranes, thus conferring broad-spectrum activity against gram-positive and gram-negative bacteria, including vancomycin- and methicillin-resistant strains.

[0036] The compounds described herein include a CSA moiety conjugated to a bone-binding moiety via a linker. The CSA moiety can be any suitable CSA, for example, CSA-8, CSA-13, CSA-44, CSA-90, CSA-91, CSA-124, CSA-131, CSA-133, CSA-138, CSA-142, CSA-144, CSA-190, CSA-191, or CSA-192. In some examples, the CSA is

[0037] [ka]

[0038] [ka]

[0039] is selected from the group consisting of: In some embodiments, the CSA portion is CSA-13, CSA-90, or CSA-131. In certain examples, the CSA portion is CSA-90.

[0040] The CSA moiety can be attached to the linker through an amino group on the CSA moiety or to a linker conjugated to the alkyl side of the CSA molecule. Example CSAs and methods for their manufacture are disclosed in U.S. Patent Nos. 6,350,738, 6,486,148, 6,767,904, 7,598,234, 7,754,705, 8,691,252, 8,975,310, 9,434,759, 9,527,883, 9,943,614, 10,155,788, 11,155,790, and 12,162, and are incorporated herein by reference in their entirety. Nos. 0,227,376, 10,370,403, and 10,626,139, U.S. Patent Publication Nos. 2016 / 0311850 and 2017 / 0210776, and U.S. Provisional Patent Application Nos. 63 / 025,255 and 63 / 028,249, which patents, publications, and patent applications are incorporated herein by reference.

[0041] Bone attachment part The bone-binding moiety described herein is a chemical group that binds to bone, thereby targeting the compounds of the present disclosure to bone. The bone-binding ability of a particular moiety can be assayed in several different ways. For example, bone binding can be assayed by binding to hydroxyapatite (HA), a mineral that is the main inorganic component of bone. Hydroxyapatite (HA) affinity assay can be performed by incubating a compound conjugated to a moiety in i) water and ii) water containing HA. If the moiety is bone-binding, the amount of compound detected in the aqueous phase of the HA solution is expected to decrease as the compound binds or absorbs to the HA surface (see, for example, Example 4). As a control, a compound that lacks a bone-binding moiety can be assayed in the same way. Those skilled in the art will be familiar with other methods that can evaluate the bone-binding ability of a particular moiety.

[0042] Suitable bone-binding moieties for use in the present disclosure may include, for example, polyhydoxy-containing moieties, tetracycline derivatives, acidic amino acids or peptides, hydroxylated heterocycles, monophosphonates, bisphosphonates, antibodies or antigen-binding fragments. In some embodiments, the bone-binding moiety is a bisphosphonate.

[0043] Bisphosphonates generally contain a phosphate-carbon-phosphate backbone and bind to hydroxyapatite (HA), the main mineral component found in bone, by coordination between the phosphate group of the bisphosphonate and calcium ions in HA. The bisphosphonate can be attached to the linker through either its terminal functional group (amine group in amino-bisphosphonates), geminal carbon, or its phosphate group. In some embodiments, the linker is attached to the bisphosphonate through a terminal functional group, such as an amino group or a hydroxy group, or other reactive group, attached to the geminal carbon of the bisphosphonate. Examples of bisphosphonate bone-binding moieties that can be used according to the present disclosure can include etidronate, clodronate, tiludronate, pamidronate, medronate, etidronate, neridronate, olpadronate, alendronate, ibandronate, aminomethylenediphosphonate, risedronate, and zoledronate. Preferably, the bone-binding moiety is alendronate. Linkers and Compound Variants Formula (I): BLC(I) where B is a bone-binding moiety, L is a linker, and C is CSA. The linkers described herein covalently link the CSA moiety to the bone-binding moiety as shown in Figure 1. It will be understood that formula (I) is non-directional and can be equivalently represented as CLB.

[0044] The linker may be small, consisting of a single covalent bond, or the linker may be a larger moiety, up to or greater than 10 kDa. In some embodiments, the linker has a molecular weight of less than about 10 kDa, e.g., less than about 9 kDa, or less than about 8 kDa, or less than about 7 kDa, or less than about 6 kDa, or less than about 5 kDa, or less than about 4 kDa, or less than about 3 kDa, or less than about 2 kDa, e.g., about 1 kDa or less. In certain examples, the linker is between about 0.2 kDa and 10 kDa, e.g., between about 0.3 kDa and 9 kDa, or between about 0.4 kDa and 8 kDa, or between about 0.5 kDa and 7 kDa, or between about 0.5 kDa and 6 kDa, or between about 0.5 kDa and 5 kDa, or between about 0.5 kDa and 4 kDa, or between about 0.5 kDa and 3 kDa, or between about 0.5 kDa and 2 kDa, or between about 0.5 kDa and 1.5 kDa.

[0045] The linker may include, for example, an ether, an ester, a thioester, a phosphoester, an amide, a peptide (e.g., a dipeptide), a polypeptide, a polysaccharide, a hydrophobic linker (e.g., a strait alkane, a fatty acid, etc.), or any combination thereof. The linker may be a cleavable linker, for example, a hydrolyzable linker (e.g., a carbamate linker) or a cathepsin-sensitive linker, or a non-cleavable linker. The linker is preferably stable in the bloodstream for a period of time sufficient to allow the compound to reach the bone (e.g., more than 1 hour, e.g., more than 6 hours, or more than 12 hours, or more than 18 hours, or more than 24 hours). The linker may be hydrophilic. In some embodiments, the linker is or includes polyethylene glycol (PEG). The PEG linker may have a molecular weight as defined in the previous paragraph.

[0046] In one embodiment, the linker has the structure of formula (II):

[0047] [ka]

[0048] (In the formula, X is independently selected from O and S; T is absent or is an alkanediyl group having 1 to 15 carbon atoms; Y is absent or is an alkanediyl group having 1 to 15 carbon atoms; n is an integer from 1 to 30; The wavy lines represent the attachment points to the CSA and bone junction. has.

[0049] T can be an alkanediyl group having 1 to 12 carbon atoms, or 1 to 10 carbon atoms, or 1 to 8 carbon atoms, or 1 to 6 carbon atoms, or 1 to 5 carbon atoms, or 1 to 4 carbon atoms.

[0050] Y can be an alkanediyl group having 1 to 12 carbon atoms, or 1 to 10 carbon atoms, or 1 to 8 carbon atoms, or 1 to 6 carbon atoms, or 1 to 5 carbon atoms, or 1 to 4 carbon atoms.

[0051] In some embodiments, T and Y are -CH2CH2-. n can be an integer from about 2 to about 25, or from about 2 to about 25, or from about 3 to about 25, or from about 4 to about 25, or from about 5 to about 25, or from about 6 to about 25, or from about 2 to about 20, or from about 2 to about 20, or from about 3 to about 20, or from about 4 to about 20, or from about 5 to about 20, or from about 6 to about 20, or from about 10 to about 30, or from about 10 to about 25, or from about 10 to about 20, or from about 15 to about 25, or from about 12 to about 20.

[0052] In some embodiments, the linker may be attached to the CSA moiety through an amino group of the CSA. Similarly, the linker may be attached to the bone-binding moiety through an amino group of the bone-binding moiety. The compound represented by formula (I) may include other features, such as additional conjugates or moieties. For example, the compound may include a second antibiotic moiety in addition to CSA. In such an example, CSA may be directly conjugated to the second antibiotic moiety, for example in the form of BLC-A2, where A2 is the second antibiotic moiety. Alternatively, CSA and the second antibiotic moiety may be attached to opposite ends of the compound, for example in the form of A2-BLC. Suitable second antibiotics include ciprofloxacin, gemcitabine, paclitaxel, cytarabine, rifalazil, norfloxacin, enoxacin, gatifloxacin, moxifloxacin, fluoroquinolone esters, benzoxazinorifamycins, aminoglycosides, polyenes, nitroimidazoles, rifamycins, bacitracin, beta-lactams, cephalosporins, chloramphenicol, glycopeptides. , macrolides, lincosamides, penicillins, quinolones, rifampicin, tetracyclines, trimethoprim, sulfonamides, amoxicillin, augmentin, amoxicillin, ampicillin, azlocillin, flucloxacillin, mezlocillin, methicillin, cephalexin, cefazedone, cefuroxime, loracarbef, cemetazole, cefotetan, cefoxitin, ciprofloxacin Sasin, Levaquin, Floxacin, Doxycycline, Minocycline, Gentamicin, Amikacin, Tobramycin, Clarithromycin, Azithromycin, Erythromycin, Daptomycin, Neomycin, Kanamycin, Streptomycin, Nisin, Epidermin, Gallidennin, Cinnamycin, Duramycin, Lacticin 481, Amoxicillin, Amoxicillin / Clavulanic Acid, Metronidazole, Clindamycin, Chlortetracycline, Dcmeclocycline, Oxytetracycline, Amikacin, Netilmicin, Cefadroxil, Cefazolin, Cephalexin, Cephalothin, Cephapirin, Cephradine, Cefaclor, Cefamandole, Cefamethazole, Cefonicid, Cefotetan, Cefoxitin, Cefpodoxime,Cefprozil, cefuroxime, cefdinir, cefixime, cefoperazone, cefotaxime, ceftazidime, ceftibuten, ceftizoxime, ceftriaxone, cefepime, azithromycin, claforan, clarithromycin, dirithromycin, erythromycin, lincomycin, troleandomycin, bacampicillin, carbenicillin, cloxacillin, dicloxacillin, methicillin, mezlocillin, nafcillin, oxacillin, piperacillin, ticarcillin, cinoxacin, ciprofloxacin, enoxacin, grepafloxacin, levofloxacin, lomefloxacin, nari may include dixic acid, norfloxacin, ofloxacin, sparfloxacin, sulfisoxazole, sulfacytine, sulfadiazine, sulfamethoxazole, sulfisoxazole, dapson, aztreonam, capreomycin, clofazimine, colistimethate, colistin, cycloserine, fosfomycin, furazolidone, methenamine, nitrofurantoin, pentamidine, rifabutin, spectinomycin, tigecycline, trimethoprim, trimetrexate glucuronate, vancomycin, chlorhexidine, carbapenem, or ertapenem.

[0053] The compound may contain two or more bone-binding moieties. For example, the bone-binding moieties may be directly attached to each other, for example in the form of B1-B2-LC, or the bone-binding moieties may be attached to opposite ends of the compound, for example in the form of B1-LC-B2, where B1 and B2 are the same or different bone-binding moieties. Further combinations and additions of antibiotics and bone-binding moieties are anticipated by the present disclosure and will be apparent to one of skill in the art.

[0054] In one particular example, the present disclosure provides a compound of formula (III) (BBA-1):

[0055] [ka]

[0056] (In the formula, n is 1 to 100.) In certain examples, n is 1-95, or 1-90, or 1-85, or 1-80, or 1-75, or 1-70, or 1-65, or 1-60, or 1-55, or 1-50, or 1-45, or 1-40, or 1-35, or 1-30, or 5-30, or 5-25, or 5-20, or 10-20. The compound may have a molecular weight of about 1 kDa to 10 kDa, for example, about 1 kDa to 9 kDa, or about 1 kDa to 8 kDa, or about 1 kDa to 7 kDa, or about 1 kDa to 6 kDa, or about 1 kDa to 5 kDa, or about 1 kDa to 4 kDa, or about 1 kDa to 3 kDa, or about 1.5 kDa to 3 kDa, or about 1.5 kDa to 2.5 kDa, or about 1.75 kDa to 2.25 kDa, for example about 2 kDa.

[0057] In one particular example, the present disclosure provides a compound of formula (IV) (BBA-2):

[0058] [ka]

[0059] The present invention provides a compound having the structure shown below: For example, compounds of formula (I) can be prepared by reacting an appropriately functionalized linker with CSA and a bone-binding moiety. One such example is shown in Scheme 1 below.

[0060] [ka]

[0061] In scheme 1, a bone-binding moiety having an amino group is reacted with a linker functionalized with two terminal carboxylic acid groups (one carboxylic acid group can be activated) to provide an intermediate in which the bone-binding moiety is linked to the linker via an amide bond. The carboxylic acid present in the intermediate then reacts with the amino group of CSA to generate another amide bond, thereby providing a compound of formula (I). Those skilled in the art will be familiar with alternative synthetic methods that can be used to prepare compounds of formula I.

[0062] Methods and Compositions The compounds described herein can be used to target bone by their bone-binding moiety and treat bone infection.The infection can be bacterial infection, for example, gram-positive bacterial infection or gram-negative bacterial infection.In some cases, the bacterial infection is staphylococcus or pseudomonas infection, for example, Staphylococcus aureus, Staphylococcus epidermidis, or Pseudomonas aeruginosa infection, for example, methicillin-resistant Staphylococcus aureus, methicillin-resistant Staphylococcus epidermidis, or tobramycin-resistant Pseudomonas aeruginosa infection.In some cases, the bacterial infection is vancomycin-resistant Staphylococcus aureus. Staphylococcus epidermidis is sometimes considered a less virulent pathogen than Staphylococcus aureus, but reports indicate that Staphylococcus epidermidis strains can acquire more invasive properties and are quite real in forming biofilms, especially on orthopedic implants (Gill et al. J Bacteriol. 2005.187:2426-2438). In some cases, the bacterial infection is an Aggregatibacter actinomycetemcomitans infection. Aggregatibacter actinomycetemcomitans is commonly observed in cases of osteomyelitis of the jaw.

[0063] In another embodiment, the bone infection is a fungal infection, for example an infection caused by the genus Candida. In some embodiments, the infection results from an orthopedic implant, osteomyelitis, or a surgical site infection. In some embodiments, the disclosed compounds are useful for the treatment of infection, and in other embodiments, the disclosed compounds are useful for the prevention of infection in subjects susceptible to or at risk for bone infection.

[0064] Also, CSA, such as CSA-13, CSA-90, and CSA-131, have been reported to promote or improve bone formation (U.S. Pat. No. 9,694,019; Schindeler et al. J Bone Joint Surg Am. 2015.97(4):302-309). In that regard, the compounds described herein can be used to promote bone formation in a subject. Bone disorders that can be treated according to the present disclosure include, for example, bone fractures, spinal cord injuries, degenerative disc disease, Paget's disease, bone cancer, and osteoporosis. Fractures that can be treated using the compositions and methods of the present disclosure include non-union fractures, simple fractures, greenstick fractures, compound fractures, comminuted (multi-fragment) fractures, impacted fractures, compound fractures, hairline fractures, compression fractures, fatigue fractures, and / or pathological fractures. Examples of fractures that can be advantageously treated by the methods described herein include, but are not limited to, fractures of the spine, lower limbs, and arms. A further example of a fracture that can be advantageously treated according to the present disclosure is a vertebral compression fracture. Such fractures occur when one or more of the bones of the spine fracture or collapse, typically when the vertebrae are already weakened, for example as a result of aging or a disease that weakens the bones, such as osteoporosis, Paget's disease, or bone cancer. In some cases, bone diseases or conditions that can be treated according to the present disclosure include bone resorption, osteoarthritis, osteoporosis, osteomalacia, osteitis fibrosa cysticis, osteochondritis dissecans, osteomalacia, osteomyelitis, osteoblastogenesis, osteopenia, osteonecrosis, and porotic hyperostosis.

[0065] The disclosed compositions and methods can be used to treat subjects suffering from imbalance in bone formation and resorption.Imbalance in bone formation and resorption usually causes bone loss, which can lead to bone-related diseases, such as osteoporosis, rickets, and osteomalacia.These bone diseases are accompanied by increased risk of fracture, increased severity of fracture, and delayed healing period.In addition, age or injury increases the occurrence of degenerative disc disease or spinal deformity, leading to spondylolisthesis.

[0066] Dosage may vary according to the type and severity of the condition to be treated, and may include a single dose or multiple doses. A particular dosage regimen may be adjusted over time according to individual need and the professional judgment of the practitioner administering the compound. When administered to a human subject, dosage regimen may vary depending on various factors, including the type and severity of infection or condition; the age, sex, weight, or health of the subject; and the route of administration. In that respect, the exact amount of the compound to be administered may depend on the judgment of the practitioner. In some embodiments, the subject may be a mammal. In some embodiments, the subject is a human, a companion animal (e.g., dog, cat, ferret, hamster, gerbil, etc.), a livestock animal (e.g., cow, pig, horse, poultry, etc.), or any other mammal that requires treatment.

[0067] The compounds described herein may be administered for a period of hours, days, weeks, or months, depending on several factors, including the severity of the infection or condition being treated, whether recurrence is expected. Administration may be by infusion for a period of hours, days, weeks, months, etc. Alternatively, administration may be intermittent, for example, once a day for a period of several days, once an hour for a period of several hours, or any other such schedule that is deemed suitable. In some embodiments, the compositions of the present disclosure are administered once a day for at least one week, for example, at least once a day for at least two weeks, or once a day for at least one month or longer. In other embodiments, the compositions of the present disclosure are provided immediately before or after exposure to an infectious agent, or at the onset of risk of bone infection.

[0068] In some examples, the compounds of the present disclosure are administered in an amount of about 0.01 mg / kg to 1000 mg / kg of body weight. For example, the compounds of the present disclosure may be administered in an amount of about 0.1 mg / kg to 900 mg / kg, or about 0.5 mg / kg to 800 mg / kg, or about 1 mg / kg to 750 mg / kg, or about 1.5 mg / kg to 700 mg / kg, or about 2 mg / kg to 600 mg / kg, or about 2 mg / kg to 500 mg / kg, or about 2.5 mg / kg to 450 mg / kg, or about 3 mg / kg to 350 mg / kg, or about 3.5 mg / kg to 250 mg / kg, or about 4 mg / kg to 200 mg / kg, or about 4 mg / kg to 100 mg / kg, or about 4 mg / kg to 50 mg / kg, or about 4 mg / kg to 20 mg / kg, or any dose bounded by these ranges. In some embodiments, the compounds of the present disclosure are administered at about 2 mg / kg, about 5 mg / kg, about 8 mg / kg, about 10 mg / kg, about 15 mg / kg, about 20 mg / kg, about 25 mg / kg, about 30 mg / kg, about 35 mg / kg, about 40 mg / kg, about 45 mg / kg, or about 50 mg / kg, or within any range bounded by the above dosage amounts. In some examples, the antibiotic compound is administered systemically.

[0069] It will be appreciated that the targeting provided by the bone-binding portion can reduce the dosage required to provide an effective amount of antibiotic (e.g., CSA) at the site of infection, compared to the dosage that would be required in the absence of the bone-binding portion. It will also be appreciated that a higher dose of the bone-binding compound can be tolerated by the patient, compared to the tolerated dose of an antibiotic compound that lacks bone-binding ability, because the bone-binding antibiotic compound is directed to the tissue of interest, rather than non-specifically migrating elsewhere in the body.

[0070] In some examples, the disclosure provides a pharmaceutical composition that contains from about 0.01 mg to 4000 mg of active ingredient, e.g., from about 0.05 mg to 3500 mg, or from about 0.1 mg to 3000 mg, from about 0.5 mg to 2500 mg, from about 0.75 mg to 2000 mg, or from about 1 mg to 1750 mg, from about 1.25 mg to 1500 mg, or from about 1.5 mg to 1250 mg, or from about 2 mg to 1000 mg, or from about 5 mg to 900 mg. In one embodiment, the oral dose of the active ingredient is about 0.00 mg, about 7.5 mg to 800 mg, or about 10 mg to 700 mg, or about 15 mg to 600 mg, or about 20 mg to 550 mg, or about 25 mg to 500 mg, or about 30 mg to 500 mg, or about 35 mg to 450 mg, or about 40 mg to 450 mg, or about 45 mg to 450 mg, or about 50 mg to 400 mg.

[0071] Techniques for formulation and administration may be found in "Remington's Pharmaceutical Sciences," Mack Publishing Co., Easton, Pa., latest edition. Suitable routes may include, for example, oral, rectal, transmucosal, or intestinal administration; intramuscular, subcutaneous, transcutaneous, intradermal, or intramedullary delivery (e.g., injection), and parenteral delivery, including intrathecal, direct intraventricular, intravenous, intraperitoneal, intranasal, pulmonary, transdermal, or intraocular delivery (e.g., injection).

[0072] The components may be formulated to allow release over an extended period of time. The release system may include a matrix of biodegradable materials or materials that release incorporated components by diffusion. The components may be distributed uniformly or non-uniformly within the release system. A variety of release systems may be useful, however, the selection of the appropriate system depends on the release rate required for a particular application. Both non-degradable and degradable release systems may be used. Suitable release systems include polymers and polymer matrices, non-polymer matrices, or inorganic and organic excipients, and diluents, such as, but not limited to, calcium carbonate and sugars (e.g., trehalose). The release system material may be selected such that components with different molecular weights are released by diffusion or through the degradation of the material. Representative synthetic biodegradable polymers include, for example: polyamides, such as poly(amino acids) and poly(peptides); polyesters, such as poly(lactic acid), poly(glycolic acid), poly(lactic-co-glycolic acid), and poly(caprolactone); poly(anhydrides); polyorthoesters; polycarbonates; and chemical derivatives thereof (substitution, addition of chemical groups, e.g., alkyl, alkylene; hydroxylation; oxidation; and other modifications routinely performed by one of skill in the art), copolymers and mixtures thereof. Representative synthetic non-degradable polymers include, for example: polyethers, such as poly(ethylene oxide), poly(ethylene glycol), and poly(tetramethylene oxide); vinyl polymers-polyacrylates and polymethacrylates, such as methyl, ethyl, other alkyl, hydroxyethyl methacrylates, acrylic and methacrylic acid, and others, such as poly(vinyl alcohol), poly(vinyl pyrrolidone), and poly(vinyl acetate); poly(urethanes); cellulose and its derivatives, such as alkyl, hydroxyalkyl, ethers, esters, nitrocellulose, and various cellulose acetates; polysiloxanes; and any chemical derivatives thereof (substitution, addition of chemical groups, such as alkyl, alkylene; hydroxylation; oxidation; and other modifications routinely performed by those skilled in the art), copolymers and mixtures thereof. Poly(lactide-co-glycolide) microspheres or nanospheres can be used.

[0073] The compounds of the present disclosure may be administered in combination with additional antibiotic agents. Suitable antibiotic agents include, for example, ciprofloxacin, gemcitabine, tryptophan, paclitaxel, cytarabine, rifalazil, norfloxacin, enoxacin, gatifloxacin, moxifloxacin, fluoroquinolone esters, benzoxazinorifamycins, aminoglycosides, polyenes, nitroimidazoles, rifamycins, bacitracin, beta-lactams, cephalosporins, chloramphenicol, glycopeptides, macrolides, lincosamides, penicillins, quinolones, rifampicin, tetracyclines, Trimethoprim, sulfonamides, amoxicillin, augmentin, amoxicillin, ampicillin, azlocillin, flucloxacillin, mezlocillin, methicillin, cephalexin, cefazedone, cefuroxime, loracarbef, cemetazole, cefotetan, cefoxitin, ciprofloxacin, levaquin, floxacin, doxycycline, minocycline, gentamicin, amikacin, tobramycin, clarithromycin, azithromycin, erythromycin, daptomycin, neomycin , kanamycin, streptomycin, nisin, epidermin, gallidennin, cinnamycin, duramycin, lacticin 481, amoxicillin, amoxicillin / clavulanic acid, metronidazole, clindamycin, chlortetracycline, dcmeclocycline, oxytetracycline, amikacin, netilmicin, cefadroxil, cefazolin, cephalexin, cephalothin, cephapirin, cephradine, cefaclor, cefamandole , cephametazole, cefonicid, cefotetan, cefoxitin, cefpodoxime, cefprozil, cefuroxime, cefdinir, cefixime, cefoperazone, cefotaxime, ceftazidime, ceftibuten, ceftizoxime, ceftriaxone, cefepime, azithromycin, claforan, clarithromycin, dirithromycin, erythromycin, lincomycin, troleandomycin, bacampicillin, carbenicillin, cloxacillin, dicloxacillin, methicillin, mezlocillin, nafcillin, oxacillin,Piperacillin, ticarcillin, cinoxacin, ciprofloxacin, enoxacin, grepafloxacin, levofloxacin, lomefloxacin, nalidixic acid, norfloxacin, ofloxacin, sparfloxacin, sulfisoxazole, sulfacytine, sulfadiazine, sulfamethoxazole, sulfisoxazole, dapson, aztreonam, capreomycin, clofazimine, colistimethate, colistin, cycloserine, fosfomycin, furazolidone, methenamine, nitrofurantoin, pentamidine, rifabutin, spectinomycin, tigecycline, trimethoprim, trimetrexate glucuronate, vancomycin, chlorhexidine, carbapenem, or ertapenem.

[0074] The compounds of the present disclosure may be administered in combination with additional compounds useful for promoting bone formation or reducing bone resorption. For example, suitable compounds may include risedronate (Actonel), ibandronate (Boniva), or zoledronic acid (Reclast or Aclasta). Alternatively or additionally, the other compound may be a corticosteroid, such as prednisone or cortisone. Alternatively or additionally, the other compound may be denosumab (Prolia). Alternatively or additionally, the other compound may be strontium ranelate (Protos). Alternatively or additionally, the other compound may be a selective estrogen receptor modulator (SERMS), such as raloxifene (Evista). Alternatively or additionally, the other compound may be a drug used in hormone replacement therapy (HRT), such as estrogen or progesterone. Alternatively or additionally, the other compound may be teriparatide (Forteo). Alternatively or additionally, the other compound may be a nonsteroidal anti-inflammatory or analgesic.For example, a suitable nonsteroidal anti-inflammatory may be ibuprofen, naproxen, aspirin; or a COX-1 and / or COX-2 inhibitor selected from ketoprofen, indomethacin (Indocin or Tivorbex), and fenoprofen (Nalfon).

[0075] The compound of the present disclosure can be administered to a subject with a scaffold.The scaffold material can be as described in U.S. Patent No. 5,681,872, U.S. Patent No. 5,914,356, U.S. Patent No. 5,939,039, U.S. Patent No. 6,325,987, U.S. Patent No. 6,383,519, U.S. Patent No. 6,521,246, U.S. Patent No. 6,736,799, U.S. Patent No. 6,800,245, U.S. Patent No. 6,969,501, U.S. Patent No. 6,991,803, U.S. Patent No. 7,052,517, U.S. Patent No. 7,189,263, U.S. Patent No. 7,534,451, U.S. Patent No. 8,303,967, U.S. Patent No. 8,460,686, or U.S. Patent No. 8,647,614, which are incorporated by reference. Other suitable scaffold materials may include VITOSS®, CORTOSS®, biopolymers, bone, decellularized bone, extracellular matrix or components thereof, fibronectin, laminin collagen, chitosan, alginate, calcium phosphate, calcium sulfate, poly(alpha-hydroxy acid), such as poly(lactic-co-glycolic acid) and polyglycolic acid, CUPE polymer, polyethylene glycol, or any combination thereof. The scaffold material may be porous. The scaffold material may be a natural material, a synthetic material, or a combination thereof. The scaffold material may be biocompatible, non-toxic, and / or non-inflammatory. The scaffold material may support cell attachment, cell proliferation, extracellular matrix and / or bone matrix production, and / or cell transformation. The scaffold material may be biodegradable. The scaffold material may be sterilized. Other scaffold materials and attributes will be appreciated by those skilled in the art.

[0076] The compounds of the present disclosure can be administered by various routes. In some embodiments, the compounds are administered systemically, for example, by direct delivery to the bloodstream of a subject. In certain embodiments, the compounds are delivered parenterally. Exemplary parenteral administration routes include, but are not limited to, intravascular, intracapsular, intraorbital, intracardiac, intradermal, transtracheal, intraperitoneal, intraventricular, intraventricular, intrathecal, subcutaneous, subcuticular, subcapsular, subarachnoid, intraspinal, epidural, intrasternal, intracranial, intramuscular, intraarticular, intraarterial, intranodal, pulmonary, intranasal, transdermal, and intravenous. In certain examples, the compounds are administered intraperitoneally or intravenously.

[0077] Alternatively, the compounds may be formulated using pharma- ceutically acceptable carriers well known in the art into dosage forms suitable for oral administration, such as tablets, pills, capsules, liquids, gels, syrups, slurries, suspensions, etc. Suitable carriers may be selected from malt, gelatin, talc, calcium sulfate, vegetable oils, synthetic oils, polyols, alginic acid, phosphate buffers, emulsifying agents, isotonic saline, and pyrogen-free water. In certain instances, the compounds are administered intranasally or by inhalation (e.g., in the form of an aerosol spray appearance from a pressurized container, pump, spray, or nebulizer using a suitable propellant, such as dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, a hydrofluoroalkane, such as 1,1,1,2-tetrafluoroethane (HFA 134A3) or 1,1,1,2,3,3,3-heptafluoropropane (HFA 227EA3), carbon dioxide, or other suitable gas), or as a solid particulate powder delivered by a dry powder inhaler. EXAMPLES

[0078] Example 1 synthesis A compound called bone-binding antibiotic-1 (BBA-1) was synthesized in a two-step reaction. In the first step, NHS-PEG-COOH linker (1 kDa, 33 mg) was dissolved in 1 mL of Milli-Q water. Separately, alendronate (ALN) sodium (10.5 mg) was weighed and dissolved in 1 mL of Milli-Q water. The alendronate solution was added dropwise to the solution of NHS-PEG-COOH under continuous stirring. The pH of the reaction was monitored and adjusted to pH 7 using NaOH solution. The reaction mixture was stirred overnight at room temperature. After overnight reaction, unconjugated alendronate was precipitated by adding 3.5 mL of absolute ethanol and removed by filtration using a 0.45 μm (micron) nylon filter to obtain ALN-PEG-COOH. In the second step, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (hydrochloride EDC.HCL 30 mg) and CSA-90 (25.5 mg) were added to the filtered solution containing ALN-PEG-COOH. The reaction mixture was stirred overnight at room temperature to obtain the final conjugate product (ALN-PEG-CSA-90). The reaction solution was placed in 1 kDa dialysis tubing and dialyzed for 24 hours using water as the dialysis medium. After dialysis, the purified reaction product was lyophilized and used for identification and chemical characterization using HPLC, NMR, and FT-IR spectroscopy.

[0079] [ka]

[0080] BBA-1 has a molecular weight of about 2070.12 g / mol and its structure is

[0081] [ka]

[0082] where n is about 16. It is. Example 2 Characterization BBA-1 was characterized using high performance liquid chromatography (HPLC). With reference to FIG. 1-A, the broad peaks at 8.2 and 9.3 min were attributed to the possible conjugation of the ALN-PEG-COOH linker to the two major amino groups of CSA-90. The peak at 7.5 min was due to unreacted linker, while the peak at 2.5 min was due to EDC.HLC carbodiimide. The corresponding elution and identification of pure NHS-PEG-COOH linker at time 5 min and CSA-90 at 6.8 min using a similar method are shown in FIG. 1-B and FIG. 1-C, respectively. The faint or absent peak of CSA-90 at 6.8 min and the significant reduction of the NHS-PEG-COOH peak at 7.5 min in the BBA-1 spectrum of the BBA-1 reaction mixture (FIG. 1-A) indicate the maximum conjugation efficiency of CSA-90 to the linker.

[0083] Figure 2 shows the FT-IR spectra for alendronate (Figure 2-A), CSA-90 (Figure 2-B), NHS-PEG-COOH linker (Figure 2-C), and BBA-1 (Figure 2-D), respectively. The presence of CSA-90 in the spectrum of BBA-1 (Figure 2-D) is evident at 2867 cm -1 and 2925 cm -1 In all spectra, the peaks at 1550–1560 cm -1 and around 3300 cm -1 The peaks at 1636 cm and 1706 cm correspond to the NH bending and stretching vibrations, respectively (Figures 2A-2D). After the conjugation of CSA-90 and alendronate to the NHS-PEG-COOH linker, the stretching vibration of the C=O bond for the formation of amide bonds with CSA-90 and alendronate is observed at 1636 cm in the spectrum of BBA-1. -1 was recorded (Figure 2-D).

[0084] As described in Example 1, alendronate was conjugated to the NHS terminus of the NHS-PEG-COOH linker. In the second step, CSA-90 was conjugated to the COOH terminus of the linker using water-soluble 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide (EDC.HCL). Excess EDC.HCL, CSA-90, and alendronate were removed by precipitation, filtration, and dialysis. Figure 3-A shows the results of the conjugation of BBA-1, NHS-PEG-COOH, CSA-90, and sodium alendronate. 1 H NMR spectrum is shown. Successful alendronate conjugation was confirmed by 1 H NMR and 31 The results were confirmed by P NMR spectroscopy. 1 As shown in the H NMR spectrum (Figure 3-A), the corresponding peaks (a and b) at 2.01 ppm and 3.14 ppm were attributed to CH2C and CH2CH2 from alendronate, respectively, indicating successful alendronate conjugation. The disappearance of the peak characteristic of CH2-CH2 of NHS from the NHS-PEG-COOH linker further confirmed the alendronate conjugation to the NHS terminus of the linker (Figure 3A, BBA-1 and NHS-PEG-COOH spectra). Similarly, the identification of the characteristic peaks of CSA-90 at 0.93 ppm, 1.76 ppm, 2.82 ppm, and 1.25 ppm confirmed the conjugation of CSA-90 to the carboxylic acid terminus of ALN-PEG-COOH. The typical proton for ethylene oxide from the NHS-PEG-COOH linker was identified at 3.64 ppm (Figure 3A, BBA-1). In addition, alendronate conjugation 31 The corresponding peak of phosphorus (P) from alendronate at 19.42 ppm (Figure 3B, alendronate) corresponds to the phosphorus (P) peak of BBA-1. 31 The P NMR shifted to 50.06 ppm (Figure 3-B, BBA-1), indicating a qualitative positive conjugation signal.

[0085] Example 3 Antibacterial assay A modified Kirby-Bauer disk diffusion assay was performed to test the bactericidal activity of BBA-1 against common bacterial species causing bone infections. Standard 200 μg gentamicin disks and Whatman filter paper disks Nφ1 (6 mm) containing equimolar concentrations of BBA-1 or CSA-90 were prepared and compared. Briefly, 0.5 mL of Staphylococcus aureus and methicillin-resistant Staphylococcus aureus (MRSA) (OD 0.2) were diluted with 0.01% glycerol and 0.01% glycerol. 600 = bacteria 1.6×10 8 The antibiotic discs were placed on the LB agar plates and after overnight incubation, the bacterial growth inhibition zone around each antibiotic disc was measured. Furthermore, the minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) of BBA-1 were determined by standardized broth microdilution method. Briefly, 1 × 10 5 CFU / mL S. aureus and MRSA inocula were incubated with serial concentrations of BBA-1 and CSA-90. After 24 h of incubation at 37° C., the optical density / absorbance at 595 nm was recorded in triplicate.

[0086] As shown in Figures 4A and 4B, disks treated with BBA-1 significantly inhibited bacterial growth across all experiments. The antibacterial activity of BBA-1 at equimolar concentrations to CSA-90 and gentamicin was comparable against both bacterial strains. The MIC and MBC concentrations of BBA-1 against S. aureus and MRSA were 1.5 μg / mL and 3 μg / mL, respectively (Figure 4C).

[0087] Example 4 Bone binding assay The hydroxyapatite (HA) binding affinity of BBA-1 and CSA-90 was semi-quantitatively determined by incubating each compound with and without HA in milli-Q water. BBA-1 (2.42 mg) was weighed and dissolved in 4 mL of milli-Q water. Separately, HA (20 mg) was weighed and suspended in 2 mL of BBA-1 solution, and the suspension was incubated at room temperature. To analyze the reduction in peak height due to HA binding, 100 μL of the supernatant was taken at the given time points and analyzed by HPLC. Similarly, the bone-binding ability of pure CSA-90 was tested by incubating CSA-90 with and without similar concentrations of HA.

[0088] The relative peak height can be attributed to BBA-1, which was reduced by about 40% within 5 min of incubation with HA (Figure 5-B). The most significant reduction was observed after 60 min of incubation, where the relative peak height of BBA-1 was reduced by about 20% (Figure 5-A). In contrast, CSA-90 showed no or only a slight reduction in peak height even after 60 min of incubation (Figure 5-A). After 60 min of incubation, the corresponding peak height for CSA-9 was only reduced by about 85% (Figure 5-A). These findings demonstrated that a significant amount of BBA-1 bound to HA (P value ≦ 0.0001, unpaired t-test) and that the alendronate moiety conferred high affinity to HA.

[0089] Example 5 Measurement of effects on bone formation activity The parenteral compound CSA-90 has been reported to have osteogenic activity and enhance recombinant human bone morphogenetic protein-2 (rhBMP-2) in cultured cells (Schindeler et al., J Bone Joint Surg Am. 97(4):302-9 (2015)). This may provide additional benefits beyond antimicrobial protection, particularly with regard to bone injury, bone defects, or orthopedic implant osseointegration.

[0090] To test whether BBA-1 retained any of the osteogenic effects of CSA-90, MC3T3-E1 cells were differentiated in osteogenic medium with either 5 μM CSA-90 or BBA-1, with or without 50 ng / ml rhBMP-2. p-Nitrophenyl phosphate assays for alkaline phosphatase activity were performed (Sigma-Aldrich) and normalized for day 3 cells grown in osteogenic medium and α-MEM medium. Assays were performed in triplicate with two independent repeats.

[0091] Consistent with previous published findings, CSA-90 and rhBMP-2 increased alkaline phosphatase expression (Figure 6). BBA-1, both alone and in combination with rhBMP-2, demonstrated similar osteogenic potential as CSA-90.

[0092] Example 6 Measuring effects on the mevalonate pathway The parenteral compound alendronate is a bisphosphonate that affects bone resorption by functionally affecting the mevalonate pathway. It was hypothesized that conjugation through a side chain amine group could preserve bone binding affinity but abolish bone antiresorptive activity.

[0093] This was confirmed using an in vitro protein prenylation assay performed on J774.2 monocyte-macrophage lineage cells treated with a range of doses of alendronate, CSA-90, or BBA-1. The assay used was as described by Ali N et al., Small GTPases 6(4):202-11 (2015). Briefly, this involved a 24-hour incubation of cells with compounds at increasing doses of drug, followed by an in vitro prenylation assay performed on protein extracts. Immunoblotting (Western blotting) was performed to identify specimen non-prenylated proteins with bands indicative of drug activity affecting the mevalonate pathway.

[0094] Treatment with alendronate at a concentration of 25 μM produced a strong effect on protein prenylation (FIG. 7). Treatment with CSA-90 or BBA-1 did not induce significant or comparable protein prenylation effects at equimolar concentrations as alendronate treatment, indicating that conjugation of alendronate to CSA-90 via its amine group significantly improves its bone destruction inhibitory activity.

[0095] Example 7 toxicity research Preliminary toxicity studies in mice showed that BBA-1 did not cause adverse events when given intravenously at a dose of 5 mg / kg.

[0096] In a proof-of-concept study, mice were premedicated with 5 mg / kg BBA-1 (N=10 per group) 1 hour prior to surgery using a preclinical infection model. The model featured a drill hole made in the tibia of C57BL6 mice that was inoculated (1E5 CFU) with live Staphylococcus aureus (strain ATCC 12600) at the time of surgery.

[0097] No uninfected control mice tested positive in soft tissue or leg swab assays. The number of infected samples and the level of infection as measured by optical density (OD595) when cultured for localized infection (FIGS. 8 and 9) were reduced in the BBA-1 treated group compared to infected controls that did not receive BBA-1.

[0098] It will be appreciated by those of skill in the art that the compounds and methods described herein can be embodied in many other forms. Unless otherwise indicated, all numbers expressing quantities of ingredients, properties, such as molecular weight, reaction conditions, and the like, used in the specification and claims should be understood to be modified in all instances by the term "about". As used herein, the terms "about" and "approximately" mean within 10-15%, preferably within 5-10%. Thus, unless indicated to the contrary, the numerical parameters set forth in the specification and appended claims are approximations that may vary depending on the desired properties sought to be obtained by the present invention. At the very least, and not as an attempt to limit the application of the doctrine of equivalents to the scope of the claims, each numerical parameter should be construed at least in light of the numerous reported digits and by applying ordinary rounding techniques. Notwithstanding that the numerical ranges and parameters setting forth the broad scope of the invention are approximations, the numerical values ​​set forth in the specific examples are reported as precisely as possible. Any numerical values, however, inherently contain certain errors necessarily resulting from the standard deviation found in their respective testing measurements.

[0099] The terms "a," "an," "the," and similar referents used in connection with the description of the present invention (especially in connection with the claims that follow) should be construed to encompass both the singular and the plural, unless otherwise indicated herein or clearly contradicted by context. The recitation of ranges of values ​​herein is merely intended to serve as a shorthand method of individually referring to each separate value falling within the range. Unless otherwise indicated herein, each separate value is incorporated herein as if it were individually recited herein. All methods described herein can be performed in any suitable order, unless otherwise indicated herein or otherwise clearly contradicted by context. The use of any and all examples or exemplary language (e.g., "such as") provided herein is intended merely to better illuminate the invention and does not pose a limitation on the scope of the invention as otherwise claimed. No language in this specification should be construed as indicating any non-claimed element essential to the practice of the invention.

[0100] Grouping of alternative elements or embodiments of the invention disclosed herein should not be construed as limiting. Each group member may be referred to and claimed individually or in any combination with other members of the group or other elements found herein. It is anticipated that one or more members of a group may be included in or deleted from a group for reasons of convenience and / or patentability. When any such inclusion or deletion occurs, the specification contains the group as modified and is therefore deemed to satisfy all Markush group descriptions used in the appended claims.

[0101] Certain embodiments of the present invention are described herein, including the best mode known to the inventors for carrying out the invention. Of course, variations on these described embodiments will become apparent to those skilled in the art upon reading the above description. The inventors expect that such variations will be utilized by those skilled in the art as appropriate, and the inventors intend for the invention to be practiced otherwise than as specifically described herein. Accordingly, the present invention includes all modifications and equivalents of the subject matter recited in the claims appended hereto as permitted by applicable law. Moreover, any combination of the above-described elements in all possible variations of the above-described elements is encompassed by the present invention, unless otherwise indicated herein or otherwise clearly contradicted by context.

[0102] Certain embodiments disclosed herein may be further limited in the claims using the language consisting of or consisting essentially of. When used in the claims, whether as filed or added in an amendment, the transitional phrase "consisting of" excludes any element, step, or ingredient not specified in the claim. The transitional phrase "consisting essentially of" limits the claim to particular substances or steps, as well as substances or steps that do not materially affect the basic and novel characteristic(s). The embodiments of the invention so claimed are specifically or explicitly described and enabled herein.

[0103] Additionally, throughout this specification, there are numerous references to patents and printed publications. Each of the above cited references and printed publications is individually incorporated herein by reference in its entirety.

[0104] Finally, it should be understood that the embodiments of the invention disclosed herein are illustrative of the principles of the invention. Other modifications that may be used are within the scope of the invention. Thus, by way of example, and not of limitation, alternative configurations of the invention may be utilized in accordance with the teachings herein. Thus, the invention is not limited to that precisely as shown and described.

Claims

1. The following formula (I): B-L-C (I) (In the formula, B is a bone-binding moiety, said bone-binding moiety being a bisphosphonate; L is a linker; C is a cationic steroid antimicrobial (CSA) moiety. or a pharma- ceutically acceptable salt form thereof.

2. 2. The compound of claim 1, or a pharma- ceutically acceptable salt form thereof, wherein the CSA is selected from the group consisting of CSA-8, CSA-13, CSA-44, CSA-90, CSA-91, CSA-124, CSA-131, CSA-133, CSA-138, CSA-142, CSA-190, CSA-191, and CSA-192.

3. The compound of claim 2 or a pharma- ceutically acceptable salt form thereof, wherein the CSA is CSA-13, CSA-90, or CSA-131.

4. A compound described in any one of claims 1 to 3 or a pharma- ceutically acceptable salt form thereof, wherein the bisphosphonate is selected from the group consisting of etidronate, clodronate, tiludronate, pamidronate, medronate, etidronate, neridronate, olpadronate, alendronate, ibandronate, aminomethylenediphosphonate, risedronate, and zoledronate.

5. The compound of claim 4 or a pharma- ceutically acceptable salt form thereof, wherein the bisphosphonate is selected from the group consisting of alendronate, pamidronate, and neridronate.

6. 6. The compound of any one of claims 1 to 5, or a pharma- ceutically acceptable salt form thereof, wherein the linker is hydrophilic and / or has a molecular weight of less than about 2 kDa.

7. 7. The compound of claim 1, or a pharma- ceutically acceptable salt form thereof, wherein the linker comprises polyethylene glycol (PEG).

8. The linker has the following structure: 【Chemistry 1】 (In the formula, X is independently selected from O and S; T is absent or is an alkanediyl group having 1 to 15 carbon atoms; Y is absent or is an alkanediyl group having 1 to 15 carbon atoms; n is an integer from 1 to 30; The wavy lines represent the attachment points to the CSA and bone attachment portion.

8. The compound of claim 1, wherein the compound has the formula:

9. The compound according to claim 1, wherein X is O; T is an alkanediyl group having 1 to 6 carbon atoms; Y is an alkanediyl group having 1 to 6 carbon atoms; 9. The compound of claim 8, or a pharma- ceutically acceptable salt form thereof, wherein n is an integer from 10 to 20.

10. The structure: 【Chemistry 2】 (wherein n is 1 to 50, for example, n is 1 to 30). and having a molecular weight of about 1.5 kDa to 2.5 kDa, or a pharma- ceutically acceptable salt form thereof.

11. The structure: 【Chemistry 3】 10. The compound of any one of claims 1 to 9, having the formula:

12. 12. A pharmaceutical composition comprising a compound according to any one of claims 1 to 11, or a pharma- ceutically acceptable salt form thereof, and a pharma- ceutically acceptable carrier.

13. 13. The pharmaceutical composition of claim 12, which is suitable for systemic administration, e.g. oral, parenteral or intravenous administration.

14. A medicament comprising a compound according to any one of claims 1 to 11 or a pharma- ceutically acceptable salt form thereof.

15. 14. A pharmaceutical composition according to claim 12 or 13, for use in treating a bone infection in a subject.

16. 14. The pharmaceutical composition according to claim 12 or 13, for use in treating osteomyelitis in a subject.

17. The pharmaceutical composition according to claim 12 or 13, for use in promoting bone formation in a subject.

18. 14. The pharmaceutical composition according to claim 12 or 13, for use in treating bone cancer or metastatic bone cancer in a subject.

Citation Information

Patent Citations

  • Hydroxybisphosphonic acid derivatives as vectors targeting bone tissue

    JP2011508757A

  • Bifunctional hydroxybisphosphonic acid derivative

    JP2014514288A

  • Oxysterol bisphosphonate analogs for selective bone formation

    JP2017514910A

  • Bone Targeted Therapeutics and Methods of Making and Using the Same

    US20160095932A1

  • Medical devices incorporating ceragenin-containing composites

    WO2013029059A1